Eli Lilly’s Taltz is already up against Novartis’ immunology blockbuster Cosentyx in psoriasis and psoriatic arthritis. Now, Lilly looks poised to challenge the Swiss drugmaker in a third indication, too.
If Novartis thought its public statements this week would be enough to silence questions about its $1.2 million contract with President Donald Trump’s personal lawyer, Michael Cohen, it was wrong.
Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin following relapse during a treatment pause.